SCHEMBL5206282

SCHEMBL5206282

COC(=O)C(NC(=O)OCc1ccccc1)c1ccc(CNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.58
NTSR1 P30989 1/20 0.54
ATM Q13315 1/20 0.53
CTSL P07711 1/20 0.52
CTSS P25774 1/20 0.52
LMNA P02545 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
CYP3A4 P08684 1/20 0.51
MAPK1 P28482 1/20 0.51
POLB P06746 1/20 0.51
GPR55 Q9Y2T6 1/20 0.51
PPARG P37231 1/20 0.50
KDM4E B2RXH2 1/20 0.49
TACR1 P25103 1/20 0.49
TRPM8 Q7Z2W7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213562 0.92 ATM (0.60) SYKNTSR1ATMCTSLCTSS
SCHEMBL7092624 0.89 ATM (0.64) SYKNTSR1ATMCTSLCTSS
SCHEMBL7446916 0.86 HDAC1 (0.50) NTSR1CTSSMEN1KMT2AMAPT
SCHEMBL23200660 0.85 MAPT (0.52) SYKATMCTSLCTSSLMNA
SCHEMBL14485285 0.85 SYK (0.62) SYKNTSR1LMNAMEN1KMT2A
SCHEMBL7451771 0.84 MAPT (0.47) NTSR1CTSSMEN1KMT2AGAA
SCHEMBL6897765 0.82 CTSS (0.62) SYKATMCTSLCTSSCYP3A4
SCHEMBL13168601 0.82 ATM (0.69) ATMCTSLCTSSLMNAMEN1
SCHEMBL16215928 0.82 ATM (0.69) ATMCTSLCTSSLMNAMEN1
SCHEMBL2574965 0.82 CTSS (0.54) SYKATMCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343561-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
EP-1240154-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 US disclosed
US-6916957-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2005-07-12 US disclosed
EP-1343561-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2003-09-17 EP disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 US disclosed
WO-2002047762-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 SYK 2489/4885NTSR1 1150/4885ATM 3243/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 SYK 2804/4885NTSR1 1572/4885ATM 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.